{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:10:04Z","timestamp":1760058604101,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,9]]},"DOI":"10.7759\/cureus.94227","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:12:47Z","timestamp":1760029967000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Online Adaptive MRI-Guided Stereotactic Body Radiotherapy (SBRT) With an Integrated Boost to the Dominant Lesion in Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Kyle R","family":"Padgett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"Sensoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew C","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Studenski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayden","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"de la Zerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak P","family":"Nejad-Davarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrin","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30034-6","article-title":"MRI-guided adaptive radiotherapy for liver tumours: visualising the future","volume":"21","author":"Witt JS","year":"2020","unstructured":"Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future. Lancet Oncol. 2020, 21:74-82. 10.1016\/S1470-2045(20)30034-6","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2020.07.027","article-title":"Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers","volume":"77","author":"Padgett KR","year":"2020","unstructured":"Padgett KR, Simpson G, Asher D, Portelance L, Bossart E, Dogan N. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers. Phys Med. 2020, 77:54-63. 10.1016\/j.ejmp.2020.07.027","journal-title":"Phys Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.12968","article-title":"Magnetic resonance-guided radiation therapy: a review","volume":"64","author":"Chin S","year":"2020","unstructured":"Chin S, Eccles CL, McWilliam A, et al.. Magnetic resonance-guided radiation therapy: a review. J Med Imaging Radiat Oncol. 2020, 64:163-77. 10.1111\/1754-9485.12968","journal-title":"J Med Imaging Radiat Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/54\/12\/N01","article-title":"Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept","volume":"54","author":"Raaymakers BW","year":"2009","unstructured":"Raaymakers BW, Lagendijk JJ, Overweg J, et al.. Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol. 2009, 54:N229-37. 10.1088\/0031-9155\/54\/12\/N01","journal-title":"Phys Med Biol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.12551","article-title":"Geometric and dosimetric impact of anatomical changes for MR-only radiation therapy for the prostate","volume":"20","author":"Nejad-Davarani SP","year":"2019","unstructured":"Nejad-Davarani SP, Sevak P, Moncion M, et al.. Geometric and dosimetric impact of anatomical changes for MR-only radiation therapy for the prostate. J Appl Clin Med Phys. 2019, 20:10-7. 10.1002\/acm2.12551","journal-title":"J Appl Clin Med Phys"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.03.032","article-title":"First experience of autonomous, un-supervised treatment planning integrated in adaptive MR-guided radiotherapy and delivered to a patient with prostate cancer","volume":"159","author":"K\u00fcnzel LA","year":"2021","unstructured":"K\u00fcnzel LA, Nachbar M, Hagm\u00fcller M, Gani C, Boeke S, Zips D, Thorwarth D. First experience of autonomous, un-supervised treatment planning integrated in adaptive MR-guided radiotherapy and delivered to a patient with prostate cancer. Radiother Oncol. 2021, 159:197-201. 10.1016\/j.radonc.2021.03.032","journal-title":"Radiother Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2019.03.006","article-title":"Prostate cancer: advantages and disadvantages of MR-guided RT","volume":"18","author":"Murray J","year":"2019","unstructured":"Murray J, Tree AC. Prostate cancer: advantages and disadvantages of MR-guided RT. Clin Transl Radiat Oncol. 2019, 18:68-73. 10.1016\/j.ctro.2019.03.006","journal-title":"Clin Transl Radiat Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109761","article-title":"Comparing adaptation strategies in MRI-guided online adaptive radiotherapy for prostate cancer: implications for treatment margins","volume":"186","author":"Dassen MG","year":"2023","unstructured":"Dassen MG, Janssen T, Kusters M, Pos F, Kerkmeijer LG, van der Heide UA, van der Bijl E. Comparing adaptation strategies in MRI-guided online adaptive radiotherapy for prostate cancer: implications for treatment margins. Radiother Oncol. 2023, 186:109761. 10.1016\/j.radonc.2023.109761","journal-title":"Radiother Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer: results from a multi-institutional clinical trial","volume":"59","author":"Hannan R","year":"2016","unstructured":"Hannan R, Tumati V, Xie XJ, et al.. Stereotactic body radiation therapy for low and intermediate risk prostate cancer: results from a multi-institutional clinical trial. Eur J Cancer. 2016, 59:142-51. 10.1016\/j.ejca.2016.02.014","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer","volume":"104","author":"Zelefsky MJ","year":"2019","unstructured":"Zelefsky MJ, Kollmeier M, McBride S, et al.. Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019, 104:42-9. 10.1016\/j.ijrobp.2018.12.045","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2015.01.011","article-title":"Stereotactic body radiotherapy for prostate cancer","volume":"27","author":"Henderson DR","year":"2015","unstructured":"Henderson DR, Tree AC, van As NJ. Stereotactic body radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol). 2015, 27:270-9. 10.1016\/j.clon.2015.01.011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials","volume":"87","author":"King CR","year":"2013","unstructured":"King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, Katz A. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013, 87:939-45. 10.1016\/j.ijrobp.2013.08.019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans C","year":"2020","unstructured":"Draulans C, van der Heide UA, Haustermans K, et al.. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020, 147:92-8. 10.1016\/j.radonc.2020.03.015","journal-title":"Radiother Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME Randomized Phase III Trial","volume":"39","author":"Kerkmeijer LG","year":"2021","unstructured":"Kerkmeijer LG, Groen VH, Pos FJ, et al.. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME Randomized Phase III Trial. J Clin Oncol. 2021, 39:787-96. 10.1200\/JCO.20.02873","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1120\/jacmp.v17i3.6089","article-title":"Quantification of the margin required for treating intraprostatic lesions","volume":"17","author":"Studenski MT","year":"2016","unstructured":"Studenski MT, Valenciaga Y, Abramowitz MC, Stoyanova R, Bossart E, Dogan N, Pollack A. Quantification of the margin required for treating intraprostatic lesions. J Appl Clin Med Phys. 2016, 17:304-12. 10.1120\/jacmp.v17i3.6089","journal-title":"J Appl Clin Med Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/bjr\/tqad041","article-title":"Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review","volume":"97","author":"Winter JD","year":"2024","unstructured":"Winter JD, Reddy V, Li W, Craig T, Raman S. Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review. Br J Radiol. 2024, 97:31-40. 10.1093\/bjr\/tqad041","journal-title":"Br J Radiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2016.04.014","article-title":"MRI-guided prostate adaptive radiotherapy: a systematic review","volume":"119","author":"McPartlin AJ","year":"2016","unstructured":"McPartlin AJ, Li XA, Kershaw LE, et al.. MRI-guided prostate adaptive radiotherapy: a systematic review. Radiother Oncol. 2016, 119:371-80. 10.1016\/j.radonc.2016.04.014","journal-title":"Radiother Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-022-02021-6","article-title":"Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate","volume":"17","author":"Nierer L","year":"2022","unstructured":"Nierer L, Eze C, da Silva Mendes V, et al.. Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate. Radiat Oncol. 2022, 17:53. 10.1186\/s13014-022-02021-6","journal-title":"Radiat Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01510-w","article-title":"1.5\u2009T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment","volume":"15","author":"Alongi F","year":"2020","unstructured":"Alongi F, Rigo M, Figlia V, et al.. 1.5\u2009T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol. 2020, 15:69. 10.1186\/s13014-020-01510-w","journal-title":"Radiat Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results","volume":"105","author":"Bruynzeel AM","year":"2019","unstructured":"Bruynzeel AM, Tetar SU, Oei SS, et al.. A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results. Int J Radiat Oncol Biol Phys. 2019, 105:1086-94. 10.1016\/j.ijrobp.2019.08.007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200696","article-title":"Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity","volume":"94","author":"Ugurluer G","year":"2021","unstructured":"Ugurluer G, Atalar B, Zoto Mustafayev T, et al.. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity. Br J Radiol. 2021, 94:20200696. 10.1259\/bjr.20200696","journal-title":"Br J Radiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE Randomized Clinical Trial","volume":"9","author":"Kishan AU","year":"2023","unstructured":"Kishan AU, Ma TM, Lamb JM, et al.. Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE Randomized Clinical Trial. JAMA Oncol. 2023, 9:365-73. 10.1001\/jamaoncol.2022.6558","journal-title":"JAMA Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1821090","article-title":"Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy","volume":"60","author":"Nicosia L","year":"2021","unstructured":"Nicosia L, Sicignano G, Rigo M, et al.. Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncol. 2021, 60:215-21. 10.1080\/0284186X.2020.1821090","journal-title":"Acta Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.01.022","article-title":"Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer","volume":"157","author":"Bohoudi O","year":"2021","unstructured":"Bohoudi O, Bruynzeel AME, Tetar S, Slotman BJ, Palacios MA, Lagerwaard FJ. Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer. Radiother Oncol. 2021, 157:197-202. 10.1016\/j.radonc.2021.01.022","journal-title":"Radiother Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100934","article-title":"Magnetic resonance-guided prostate stereotactic body radiation therapy with daily online plan adaptation: results of a prospective phase 1 trial and supplemental cohort","volume":"7","author":"Leeman JE","year":"2022","unstructured":"Leeman JE, Cagney DN, Mak RH, et al.. Magnetic resonance-guided prostate stereotactic body radiation therapy with daily online plan adaptation: results of a prospective phase 1 trial and supplemental cohort. Adv Radiat Oncol. 2022, 7:100934. 10.1016\/j.adro.2022.100934","journal-title":"Adv Radiat Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.109441","article-title":"SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: an analysis of the dosimetric impact of intra-fractional organ changes","volume":"179","author":"Brennan VS","year":"2023","unstructured":"Brennan VS, Burleson S, Kostrzewa C, et al.. SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: an analysis of the dosimetric impact of intra-fractional organ changes. Radiother Oncol. 2023, 179:109441. 10.1016\/j.radonc.2022.109441","journal-title":"Radiother Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.01.052","article-title":"Phase I trial of MRI-guided prostate cancer lattice extreme ablative dose (LEAD) boost radiation therapy","volume":"107","author":"Pollack A","year":"2020","unstructured":"Pollack A, Chinea FM, Bossart E, et al.. Phase I trial of MRI-guided prostate cancer lattice extreme ablative dose (LEAD) boost radiation therapy. Int J Radiat Oncol Biol Phys. 2020, 107:305-15. 10.1016\/j.ijrobp.2020.01.052","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2019.04.007","article-title":"Technical design and concept of a 0.35 T MR-Linac","volume":"18","author":"Kl\u00fcter S","year":"2019","unstructured":"Kl\u00fcter S. Technical design and concept of a 0.35 T MR-Linac. Clin Transl Radiat Oncol. 2019, 18:98-101. 10.1016\/j.ctro.2019.04.007","journal-title":"Clin Transl Radiat Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153396","article-title":"Non-adaptive MR-guided radiotherapy for prostate SBRT: less time, equal results","volume":"10","author":"Sandoval ML","year":"2021","unstructured":"Sandoval ML, Youssef I, Latifi K, et al.. Non-adaptive MR-guided radiotherapy for prostate SBRT: less time, equal results. J Clin Med. 2021, 10:3396. 10.3390\/jcm10153396","journal-title":"J Clin Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2022.09.007","article-title":"Magnetic resonance-guided adaptive radiation therapy for prostate cancer: the first results from the MOMENTUM study: an International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy","volume":"13","author":"Teunissen FR","year":"2023","unstructured":"Teunissen FR, Willigenburg T, Tree AC, et al.. Magnetic resonance-guided adaptive radiation therapy for prostate cancer: the first results from the MOMENTUM study: an International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy. Pract Radiat Oncol. 2023, 13:261-9. 10.1016\/j.prro.2022.09.007","journal-title":"Pract Radiat Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399115-assessment-of-online-adaptive-mri-guided-stereotactic-body-radiotherapy-sbrt-with-an-integrated-boost-to-the-dominant-lesion-in-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:12:48Z","timestamp":1760029968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399115-assessment-of-online-adaptive-mri-guided-stereotactic-body-radiotherapy-sbrt-with-an-integrated-boost-to-the-dominant-lesion-in-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.94227","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}